

Surrey & North West Sussex Area Prescribing Committee (APC)

Policy Statement	Aliskiren
Policy No:	APC 438-2019
Date of Issue	August 2019
Review Date:	August 2022 (Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)

Recommendations:

The Area Prescribing Committee does not recommend the use of aliskiren.

Aliskiren will be considered BLACK on the traffic light system. Prescribers should:

- NOT initiate aliskiren for any new patient AND
- Change patients taking aliskiren to an alternative antihypertensive in line with NICE CG127 on the diagnosis and management of hypertension in adults noting that it is important that blood pressure is monitored closely and to consider treatments that may not have previously been used OR

Patients should be referred into a specialist for consideration of de-prescribing if appropriate

Key Considerations:

- NHS England guidance 'Items which should not routinely be prescribed in primary care: Guidance for CCGs' Version 2, June 2019 https://www.england.nhs.uk/wp-content/uploads/2017/11/items-which-should-not-be-routinely-precscribed-in-pc-ccg-guidance-v2.pdf
- NICE state there is insufficient evidence of its effectiveness to determine its suitability for use in resistant hypertension. Whilst aliskiren has shown comparable efficacy to other antihypertensive agents in terms of blood pressure reduction, its effects on mortality and long-term morbidity are currently unknown.

https://www.nice.org.uk/guidance/cg127/evidence

Date taken to Area Prescribing Committee	7 th August 2019
Agreed by APC members	27 th August 2019